Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 4
1951 5
1952 1
1953 7
1954 1
1955 2
1956 3
1957 1
1958 2
1959 1
1960 2
1961 1
1962 2
1964 2
1967 1
1970 2
1978 1
1980 4
1981 2
1983 3
1984 3
1985 2
1992 1
1994 1
1995 1
1996 1
1997 4
2000 1
2007 2
2009 2
2011 4
2012 9
2013 5
2014 3
2015 3
2016 3
2017 5
2018 6
2019 7
2020 13
2021 28
2022 12
2023 22
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutari P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Iannì G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Oliva EN, et al. Among authors: reda g. J Clin Oncol. 2023 Oct 1;41(28):4486-4496. doi: 10.1200/JCO.22.02699. Epub 2023 Jun 9. J Clin Oncol. 2023. PMID: 37294914 Free PMC article. Clinical Trial.
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S, Sutton LA, Ljungström V, Capasso A, Pandzic T, Weström S, Foroughi-Asl H, Skaftason A, Gellerbring A, Lyander A, Gandini F, Gaidano G, Trentin L, Bonello L, Reda G, Bödör C, Stavroyianni N, Tam CS, Marasca R, Forconi F, Panayiotidis P, Ringshausen I, Jaksic O, Frustaci AM, Iyengar S, Coscia M, Mulligan SP, Ysebaert L, Strugov V, Pavlovsky C, Walewska R, Österborg A, Cortese D, Ranghetti P, Baliakas P, Stamatopoulos K, Scarfò L, Rosenquist R, Ghia P. Bonfiglio S, et al. Among authors: reda g. Blood Adv. 2023 Jun 27;7(12):2794-2806. doi: 10.1182/bloodadvances.2022008821. Blood Adv. 2023. PMID: 36696464 Free PMC article.
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL.
Visentin A, Chatzikonstantinou T, Scarfò L, Kapetanakis A, Demosthenous C, Karakatsoulis G, Minga E, Chamou D, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Besikli-Dimou S, Bron D, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Delgado J, Dimou M, Donaldson D, Catherwood M, Doubek M, Efstathopoulou M, Eichhorst B, Elashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Collado R, Gentile M, Gimeno E, Glenthøj A, da Silva MG, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Rigolin GM, Ruchlemer R, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Tadmor T, Capasso A, Del Poeta G, Gutwein O, Karlsson LK, Milosevic I, Mirás F, Reda G, Saghumyan G… See abstract for full author list ➔ Visentin A, et al. Among authors: reda g. Am J Hematol. 2023 Dec;98(12):1856-1868. doi: 10.1002/ajh.27093. Epub 2023 Sep 29. Am J Hematol. 2023. PMID: 37772428 Free article.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: reda g. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.
Chatzikonstantinou T, Scarfò L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, Kotaskova J, Demosthenous C, Smolej L, Mulligan S, Alcoceba M, Al-Shemari S, Aurran-Schleinitz T, Bacchiarri F, Bellido M, Bijou F, Calleja A, Medina A, Khan MA, Cassin R, Chatzileontiadou S, Collado R, Christian A, Davis Z, Dimou M, Donaldson D, Santos GD, Dreta B, Efstathopoulou M, El-Ashwah S, Enrico A, Fresa A, Galimberti S, Galitzia A, García-Serra R, Gimeno E, González-Gascón-Y-Marín I, Gozzetti A, Guarente V, Guieze R, Gogia A, Gupta R, Harrop S, Hatzimichael E, Herishanu Y, Hernández-Rivas JÁ, Inchiappa L, Jaksic O, Janssen S, Kalicińska E, Laribi K, Karakus V, Kater AP, Kho B, Kislova M, Konstantinou E, Koren-Michowitz M, Kotsianidis I, Kreitman RJ, Labrador J, Lad D, Levin MD, Levy I, Longval T, Lopez-Garcia A, Marquet J, Martin-Rodríguez L, Maynadié M, Maslejova S, Mayor-Bastida C, Mihaljevic B, Milosevic I, Miras F, Moia R, Morawska M, Murru R, Nath UK, Navarro-Bailón A, Oliveira AC, Olivieri J, Oscier D, Panovska-Stavridis I, Papaioannou M, Papajík T, Kubova Z, Phumphukhieo P, Pierie C, Puiggros A, Rani L, Reda G, Rigolin GM, Ruchlemer R, Daniel de Deus Santos M, Schipani M, Schiwit… See abstract for full author list ➔ Chatzikonstantinou T, et al. Among authors: reda g. EClinicalMedicine. 2023 Nov 15;65:102307. doi: 10.1016/j.eclinm.2023.102307. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 38033506 Free PMC article.
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Morabito F, Tripepi G, Mauro FR, Laurenti L, Reda G, Moia R, Condoluci A, Vincelli I, Chiarenza A, Vigna E, Martino EA, Bruzzese A, Mezzatesta S, Laureana R, Cutrona G, Di Raimondo F, Fronza G, Zucchetto A, Bomben R, Rossi FM, Olivieri J, Zaja F, Rossi D, Gaidano G, Del Principe MI, Ilariucci F, Del Poeta G, Ferrarini M, Neri A, Gattei V, Gentile M. Morabito F, et al. Among authors: reda g. Am J Hematol. 2023 Jul;98(7):E157-E160. doi: 10.1002/ajh.26927. Epub 2023 Apr 17. Am J Hematol. 2023. PMID: 37067157 No abstract available.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: reda g. Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29. Am J Hematol. 2023. PMID: 37382471 No abstract available.
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Bomben R, Rossi FM, Vit F, Bittolo T, Zucchetto A, Papotti R, Tissino E, Pozzo F, Degan M, Polesel J, Bulian P, Marasca R, Reda G, Laurenti L, Olivieri J, Chiarenza A, Laureana R, Postorino M, Del Principe MI, Cuneo A, Gentile M, Morabito F, Fronza G, Tafuri A, Zaja F, Foà R, Di Raimondo F, Del Poeta G, Gattei V. Bomben R, et al. Among authors: reda g. Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18. Leukemia. 2023. PMID: 36807650 Free PMC article. No abstract available.
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study.
Sportoletti P, Laurenti L, Chiarenza A, Gaidano G, Albi E, Mauro FR, Trentin L, Vallisa D, Pane F, Cuneo A, Albano F, Zamprogna G, Coscia M, Gozzetti A, Reda G, Caira M, Finsinger P, Gualberti G, Iannella E, Malgieri S, Molica S. Sportoletti P, et al. Among authors: reda g. Hematol Oncol. 2024 Jan;42(1):e3216. doi: 10.1002/hon.3216. Epub 2023 Sep 29. Hematol Oncol. 2024. PMID: 37772620
178 results